Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) rose 1.6% on Thursday . The stock traded as high as $5.10 and last traded at $5.10. Approximately 500 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 781 shares. The stock had previously closed at $5.02.
Starpharma Stock Up 2.7%
The firm has a 50 day moving average price of $4.52 and a two-hundred day moving average price of $3.37.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Read More
- Five stocks we like better than Starpharma
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
- From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
